What is ASAP Solution are they talking about CS
Bob

-----Original Message-----
From: [email protected] [mailto:[email protected]]
On Behalf Of William Meyer
Sent: Friday, February 27, 2004 9:39 AM
To: [email protected]
Subject: Re: CS>5 days for Malaria



what is notable here is that no mining company can profit from "homeopathic"


silver. so, this has nothing to do with mining profits. it is a different
idea. 

On Feb 27, 2004, at 8:25 AM, Ross Craig wrote: 


Clifton Mining Company - New Human Study Data Released 

ALPINE, UT, Feb. 27 /CNW/ - Clifton Mining Company (Clifton)(OTC:CFTN) 

American Biotech Labs (a private company in which Clifton, the largest 

shareholder is releasing new human study data on use of the ASAP Solution in


west African hospitals, against a number of human ailments including malaria


and a viral infections. 


New Human Studies 


American Biotech Labs (ABL) has been working in conjunction with four 

hospitals in West Africa that have been conducting human studies of the ASAP


product as a antibiotic alternative against human ailments like malaria, 

fungal infections, ear infections, measles, septic ulcers and a number of 

serious viral problems. This is the second set of human studies released by 

the west African hospitals. The new studies found the product effective 

against all the above ailments. In conjunction with the human studies, the 

country of Ghana has approved the ASAP supplement product as a homeopathic 

drug. 


Malaria 


The past ASAP human malarial studies found the product effective in all 

of the cases averaging only five days of treatment to full recovery. This
new 

study has taken the testing to a new level checking the blood of patients 

deemed fully recovered to see if any signs of the parasites remain in the 

bloodstream. According to the data in the studies, the patients showed 

absolutely no malarial protozoans left in the bloodstream. Over 900 million 

people are estimated to have this disease, many in poor countries. Said
Keith 

Moeller, VP, "Evidence is steadily mounting that we may be able to help 

millions of people who are suffering from this disease. It is also exciting
to 

see the first human studies in which the product is being used as a
treatment 

for people who suffer from serious viral infections." Testing of the ASAP 

product continues in the African hospitals, as well as in numerous other 

facilities worldwide.